Immunologic characterization of spasmodic dysphonia patients who develop resistance to botulinum toxin

Journal of Voice

Volumn 17, Issue 2, 2003, Pages 255-264

  Park, Jong Beak ^a   Simpson, Lance L ^a,b   Anderson, Timothy D ^a   Sataloff, Robert ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

Botulinum toxin; IgA; Resistance; Spasmodic dysphonia

Indexed keywords

ANTIBODY; BOTULINUM TOXIN A; BOTULINUM TOXIN ANTIBODY; BOTULINUM TOXIN B; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; DYSPHONIA; FEMALE; HUMAN; IMMUNE STATUS; IMMUNITY; INJECTION; MAJOR CLINICAL STUDY; MALE; NEURECTOMY; SPASMODIC DYSPHONIA; WESTERN BLOTTING;

EID: 0038317884     PISSN: 08921997     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-1997(03)00072-9     Document Type: Article

References (24)

1. Cardoso F, Jankovic J. Clinical use of botulinum neurotoxins. Curr Top Microbiol. Immunol. 1995;195:123-141.
2. Jankovic J, Schwartz KS. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993;43:834-836.
3. Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991;48: 1253-1256.
4. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213-217.
5. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-1746.
6. Parnes SM, Lavorato AS, Myers EN. Study of spastic dysphonia using video fiberoptic laryngoscopy. Ann Otolaryngol. 1978;87:322-326.
7. Ludlow CL, Naunton RF, Bassich CJ. Procedures for the selection of spastic dysphonia patients for recurrent laryngeal nerve section. Otolaryngol Head Neck Surg. 1984; 92:24-31.
8. Izdebski K, Dedo HH. Spastic dysphonia. In: Darby JK, eds. Speech Evaluation in Medicine. New York: Grune & Stratton; 1981:105-127.
9. Ludlow CL, Connor NP. Dynamic aspects of phonatory control in spasmodic dysphonia. J Speech Hear Res. 1987;30:197-206.
10. Miller RH, Woodson GE, Jankovic J. Botulinum toxin injection of the vocal fold for spasmodic dysphonia: A preliminary report. Arch Otolaryngol Head Neck Surg. 1987; 113:603-605.
11. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope. 1988;98:193-197.
12. Neuenschwander MC, Pribitkin EA, Sataloff EA. Botulinum toxin in otolaryngology: A review of its actions and opportunities for use. ENT-Ear, Nose & Throat J. 2000; 79:788-801.
13. Smith ME, Ford CN. Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg. 2000;126:533-535.
14. DasGupta BR, Sathyamoorthy V. Purification and amino acid composition of type A botulinum neurotoxin. Toxicon. 1984;22:415-424.
15. Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol. 1988;26:2351-2356.
16. Zuber M, Sebald M, Bathien N, de Rocondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance. Neurology. 1993;43:1715-1718.
17. Siatowski RM, Tyutyuniko VA, Biglan AW, et al. Serum antibody to botulinum A toxin. Ophthalmology. 1993;100: 1861-1866.
18. Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallet M, eds. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994:93-107.
19. Hanna PA, Jankovic J. Mouse bioassay versus western blot assay for botulinum toxin antibodies: Correlation with clinical response. Neurology. 1998;50:1620-1624.
20. Palace J, Naine A, Hyman N, Doherty TV, Vincent A. A radioimmuno-precipitation assay for antibodies to botulinum A. Neurology. 1998;50:1463-1466.
21. Dezfulian M, Hatheway CL, Yolken RH, Bartlett JR. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type A and type B toxins in stool samples of infants with botulism. J Clin Microbiol. 1984; 20:379-383.
22. Atassi MZ, Oshima M. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit Rev Immunol. 1999;19:219-260.
23. Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie. 2000;82:955-966.
24. Tsui JK, Wong NLM, Wong E, Calne DB. Production of circulating antibodies to botulinum-A toxin in patients receiving repeated injections for dystonia [abstract]. Ann Neurol. 1988;23:181.